Pediatric Diabetes Management Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Blood Glucose Monitors (BGM), Continuous Glucose Monitors (CGM), Insulin Pumps, Insulin Pens, Insulin Syringes), By Technology (Connected Devices, Non-connected Devices), By End User (Hospitals, Homecare, Pediatric Clinics), By Region and Competition, 2020-2030F

Market Overview

The Global Pediatric Diabetes Management Market was valued at USD 5.66 Billion in 2024 and is expected to reach USD 10.01 Billion by 2030 with a CAGR of 9.94%. The Global Pediatric Diabetes Management Market is witnessing significant growth due to the increasing prevalence of diabetes among children and adolescents, which is driving demand for innovative management solutions. Pediatric diabetes, particularly type 1 diabetes, requires continuous monitoring and precise insulin administration to prevent acute complications such as diabetic ketoacidosis and long-term effects on growth and development. Advances in technology, including continuous glucose monitoring (CGM) systems, automated insulin delivery (AID) devices, and smart insulin pumps, are enabling more precise and convenient management of blood glucose levels. Hospitals, clinics, and homecare settings are increasingly integrating these solutions into care protocols, improving patient adherence and clinical outcomes. Growing awareness among parents, caregivers, and healthcare providers regarding the importance of early intervention and effective diabetes management is also contributing to the market’s expansion.

The market is being driven by several key factors. Rising incidence of pediatric diabetes globally is creating a larger patient pool that requires continuous monitoring and personalized care. Adoption of advanced insulin delivery systems and CGM devices enables better glycemic control, reducing the risk of acute emergencies and long-term complications. Healthcare providers are emphasizing patient-centric approaches, tailoring treatment plans to individual children’s needs, and leveraging digital tools to track glucose levels, adjust insulin dosing, and provide remote monitoring. Continuous advancements in medical technologies, including predictive analytics and data-driven decision-making, allow clinicians to anticipate high-risk episodes and intervene proactively. Increasing investments in research and development by medical device companies are accelerating innovation in pediatric diabetes management solutions, offering safer, more efficient, and user-friendly options for both patients and healthcare professionals.

Emerging trends in the market include the integration of connected healthcare technologies that combine CGM data with insulin delivery systems for real-time adjustments. Telemedicine platforms are supporting remote monitoring and consultation, helping families manage pediatric diabetes at home while reducing hospital visits. Personalized treatment approaches, including algorithm-driven insulin dosing, are enhancing the precision and effectiveness of care. Despite strong growth prospects, the market faces challenges such as limited awareness in certain regions, high costs of advanced devices that may restrict accessibility, and the need for specialized training of healthcare professionals to use these technologies effectively. Regulatory hurdles and concerns regarding long-term safety and efficacy of new devices may slow adoption. Addressing these challenges through education, policy support, and technological innovation is essential to sustaining growth in the Global Pediatric Diabetes Management Market, ensuring better outcomes for children living with diabetes.

Key Market Drivers

Rising Prevalence of Pediatric Diabetes

A major driver of the Global Pediatric Diabetes Management Market is the rising prevalence of pediatric diabetes, which has been increasing steadily due to a combination of genetic, environmental, and lifestyle factors. Type 1 diabetes remains the most common form among children and adolescents, requiring lifelong insulin therapy and continuous monitoring to prevent acute complications such as diabetic ketoacidosis (DKA) and long-term health issues affecting growth, cardiovascular health, and kidney function. At the same time, the incidence of type 2 diabetes is rising among younger populations, driven by childhood obesity, sedentary lifestyles, and poor dietary habits, creating an additional patient pool that requires regular monitoring, insulin therapy, and lifestyle interventions. According to the International Diabetes Federation, around 1.52 million people aged 20 years had diabetes in 2022, highlighting the significant burden of the disease and underscoring the urgent need for effective management solutions. This dual burden of type 1 and type 2 diabetes is intensifying demand for reliable pediatric diabetes management products and services.

Healthcare providers are recognizing the critical need for early diagnosis and intervention to manage glycemic levels efficiently and prevent complications. Continuous glucose monitoring (CGM) systems, automated insulin delivery (AID) devices, and smart insulin pumps are increasingly being adopted to provide real-time insights, personalized insulin dosing, and predictive alerts for hypoglycemic or hyperglycemic events. Rising prevalence is also driving investment in caregiver education programs and pediatric-specific treatment protocols, ensuring adherence to therapy and effective disease management. The increasing number of children diagnosed with diabetes is prompting healthcare systems, hospitals, and clinics to expand infrastructure, implement advanced monitoring solutions, and integrate digital health tools to improve patient outcomes. This growing patient base, combined with technological advancements and awareness initiatives, is a key factor propelling the expansion of the pediatric diabetes management market globally, reflecting the urgent need for specialized and accessible care solutions for young patients living with diabetes.

Growing Adoption of Advanced Insulin Delivery Systems

The global pediatric diabetes management landscape is undergoing a significant transformation, driven by the increasing adoption of advanced insulin delivery systems. Traditional insulin injections, often challenging for children due to pain and dosing errors, are being supplemented or replaced by technologies like smart insulin pens, insulin pumps, and automated insulin delivery (AID) systems. These innovations offer precise dosing, reduce the risk of both hyperglycemia and hypoglycemia, and enable safer, more effective management of pediatric diabetes.

A notable development in 2024 was the expansion of continuous glucose monitoring (CGM) systems into inpatient pediatric settings. While studies in neonatal and pediatric intensive care units are still emerging, the integration of CGM technology into standard care protocols is becoming more prevalent. This shift underscores the growing recognition of CGM's role in enhancing glycemic control and patient safety across various care environments.

Furthermore, the 2024 ADA Standards of Care emphasized the importance of offering AID systems to youth with type 1 diabetes capable of using the device safely, either independently or with caregivers. These guidelines advocate for the integration of AID systems into diabetes management strategies, highlighting their potential to improve glycemic outcomes and quality of life for pediatric patients. Despite these advancements, challenges remain in ensuring equitable access to these technologies. Factors such as socioeconomic disparities and healthcare infrastructure limitations can affect the availability and adoption of advanced diabetes management tools. Addressing these barriers is crucial to ensure that all pediatric patients benefit from the latest innovations in diabetes care.

In conclusion, the integration of advanced insulin delivery systems and CGM technology into pediatric diabetes management is enhancing treatment precision and patient outcomes. Continued efforts to expand access and address existing disparities will be essential in realizing the full potential of these advancements for all pediatric patients.

Increasing Use of Continuous Glucose Monitoring (CGM) Systems

A significant driver of the Global Pediatric Diabetes Management Market is the increasing use of Continuous Glucose Monitoring (CGM) systems, which are transforming the way diabetes is managed in children and adolescents. CGM devices provide real-time monitoring of blood glucose levels throughout the day and night, allowing caregivers and healthcare professionals to detect fluctuations promptly and make timely adjustments to insulin therapy. This continuous feedback is particularly critical for pediatric patients, who often experience unpredictable glucose variations due to growth, hormonal changes, physical activity, and dietary habits. Unlike traditional finger-prick testing, CGM systems reduce the need for frequent invasive checks, improving compliance and reducing discomfort for children. The technology also supports early identification of hyperglycemia or hypoglycemia, which helps prevent acute complications such as diabetic ketoacidosis (DKA) and long-term consequences like neuropathy or retinopathy.

Integration of CGM devices with insulin pumps and automated insulin delivery systems enables precise, data-driven insulin administration, improving glycemic control and minimizing the risk of errors. Many CGM platforms now include mobile applications that provide caregivers with alerts, trend analysis, and detailed reporting, allowing for more proactive and personalized management. Healthcare providers can leverage CGM data to optimize treatment plans, track patient adherence, and educate families on best practices for managing pediatric diabetes. Increasing clinical evidence supporting the effectiveness of CGM in reducing hospitalizations and improving quality of life is driving adoption across hospitals, clinics, and homecare settings. Rising awareness among parents and healthcare professionals about the benefits of continuous monitoring, combined with favorable reimbursement policies in several markets, is further accelerating the adoption of CGM systems, making them a key factor propelling growth in the pediatric diabetes management market.

Download Free Sample Report

Key Market Challenges

High Cost of Advanced Devices and Therapies

A significant challenge facing the Global Pediatric Diabetes Management Market is the high cost of advanced devices and therapies, which limits accessibility for many families, particularly in low- and middle-income regions. Advanced technologies such as continuous glucose monitors (CGM), automated insulin delivery (AID) systems, and smart insulin pumps offer precision, convenience, and improved glycemic control, but their high purchase prices often ranging from USD 1,000–6,000 for pumps and USD 2,000–5,000 annually for CGM sensors create substantial financial barriers. Many families are unable to afford these technologies without adequate insurance coverage or government subsidies, resulting in disparities in pediatric diabetes care. The cost factor affects device adoption and long-term treatment adherence, as children relying on traditional finger-prick glucose meters and manual insulin injections face less precise monitoring, increasing the risk of acute complications such as diabetic ketoacidosis (DKA) and long-term health consequences.

High costs also constrain healthcare providers in standardizing advanced management solutions, especially in emerging markets with limited healthcare budgets. Manufacturers face the challenge of balancing innovation with affordability, as pediatric-specific R&D investments are substantial. To mitigate these barriers, strategies such as developing lower-cost alternatives, expanding insurance coverage, offering patient assistance programs, and implementing government subsidies are critical. Without such measures, the high expense of advanced devices and therapies will continue to impede adoption and limit the overall growth potential of the Global Pediatric Diabetes Management Market.

Complexity of Device Usage

A significant challenge faced by the Global Pediatric Diabetes Management Market is the complexity of device usage, which affects both caregivers and young patients. Advanced diabetes management solutions, including insulin pumps, continuous glucose monitoring (CGM) systems, and automated insulin delivery (AID) devices, require precise handling, calibration, and interpretation of data to function effectively. Pediatric patients, particularly younger children, often lack the technical skills and understanding necessary to operate these devices independently, making caregiver involvement critical. Caregivers must be trained to interpret glucose trends, adjust insulin doses accurately, manage device alerts, and troubleshoot malfunctions, which can be time-consuming and overwhelming, especially for families managing multiple responsibilities.

The complexity of usage also extends to integrating multiple devices within a single treatment plan. For instance, pairing CGM systems with insulin pumps or connecting devices to digital health platforms for data tracking requires a degree of technical literacy that may not be accessible to all families. Mismanagement or incorrect operation can lead to improper dosing, hypoglycemic or hyperglycemic events, and increased hospital visits, undermining the effectiveness of treatment and patient safety. Healthcare professionals face the additional burden of providing detailed training, ongoing support, and regular monitoring to ensure proper usage. In regions with limited access to specialized pediatric endocrinologists or diabetes educators, these challenges are amplified, restricting adoption and market growth. Reducing device complexity through intuitive designs, simplified interfaces, and robust caregiver support systems is essential to overcoming these barriers and ensuring effective pediatric diabetes management.

Key Market Trends

Integration of Digital Health Solutions

The integration of digital health solutions is a transformative trend in the Global Pediatric Diabetes Management Market, significantly enhancing the monitoring and management of pediatric diabetes. Digital health technologies, including mobile applications, cloud-based platforms, and telemedicine tools, allow caregivers and healthcare providers to access real-time data on blood glucose levels, insulin administration, and lifestyle factors. Continuous glucose monitoring (CGM) systems integrated with these platforms provide automated alerts for hypo- or hyperglycemic events, enabling timely interventions and reducing the risk of complications such as diabetic ketoacidosis. Integration of digital platforms with insulin pumps and automated insulin delivery (AID) systems further enhances personalized care by enabling real-time adjustments to insulin dosing based on predictive algorithms and trend analysis.

Remote monitoring capabilities offered by digital solutions allow healthcare professionals to supervise pediatric patients outside hospital settings, improving adherence and reducing the frequency of emergency visits or hospitalizations. These platforms also facilitate better communication between caregivers, patients, and clinicians, ensuring coordinated care and informed decision-making. Data collected through digital health systems can be analyzed to identify patterns in glucose fluctuations, evaluate the effectiveness of treatment protocols, and optimize long-term management strategies. Growing investment in healthcare IT infrastructure, increasing smartphone penetration, and rising awareness among parents and healthcare providers about the benefits of connected care are accelerating adoption of digital solutions. Integration of wearable sensors, artificial intelligence, and predictive analytics is enhancing the precision and efficiency of diabetes management, providing actionable insights and supporting proactive interventions. This convergence of technology and healthcare is shaping a patient-centric, data-driven approach, driving innovation and improving outcomes in pediatric diabetes management across diverse healthcare settings.

Focus on Personalized and Patient-Centric Care

The Global Pediatric Diabetes Management Market is experiencing a significant shift towards personalized and patient-centric care, particularly in India. This approach tailors treatment strategies to the unique needs of children and adolescents with diabetes, considering factors such as age, weight, activity levels, dietary patterns, and comorbid conditions. The Indian Council of Medical Research (ICMR) INDIAB study, published in 2023, reported that approximately 10.1 crore individuals in India are living with diabetes, highlighting the growing prevalence and the need for specialized pediatric care.

Healthcare providers are increasingly adopting customized care plans that integrate continuous glucose monitoring (CGM) data with smart insulin delivery systems. These technologies enable real-time adjustments to insulin dosing based on individual glucose trends, optimizing glycemic control while minimizing the risk of hypoglycemia or hyperglycemia. Moreover, personalized care extends beyond clinical management to include educational support, caregiver engagement, and behavioral interventions. Programs that empower parents and caregivers with knowledge about glucose monitoring, insulin administration, and lifestyle modifications are being widely implemented.

Digital health platforms, mobile applications, and telemedicine services are enhancing the ability to deliver tailored care remotely. These tools allow healthcare providers to monitor adherence, adjust therapy, and provide guidance without frequent hospital visits. Predictive analytics and algorithm-driven insulin dosing tools are increasingly used to anticipate high-risk events and optimize treatment regimens for each child. By emphasizing individualized therapy, minimizing treatment burden, and improving quality of life, the patient-centric model is shaping the development and adoption of advanced pediatric diabetes management solutions.

This trend is driving innovation in devices, monitoring systems, and care protocols, ensuring safer, more effective, and highly personalized management of diabetes in children and adolescents worldwide.

Segmental Insights

Product Insights

Based on the Product, Continuous Glucose Monitors (CGM) emerged as the dominant segment in the Global Pediatric Diabetes Management Market in 2024. This is due to their critical role in providing real-time glucose monitoring and improving glycemic control among pediatric patients. CGM devices allow for continuous tracking of blood glucose levels throughout the day and night, enabling caregivers and healthcare professionals to detect hyperglycemic or hypoglycemic episodes promptly. This real-time visibility is especially important for children and adolescents, who may have unpredictable activity levels and dietary patterns, making traditional finger-prick glucose monitoring less effective for timely intervention. The increasing adoption of advanced CGM systems, including sensor-based devices integrated with mobile applications and insulin pumps, is further driving the segment’s growth. These integrated solutions provide alerts, trend analysis, and predictive insights, allowing for precise insulin dosing and proactive management of diabetes. CGM devices also enhance patient convenience and compliance, reducing the discomfort associated with frequent finger-stick testing and empowering children and caregivers to manage diabetes more effectively at home.

End User Insights

Based on the End User, Hospitals emerged as the dominant segment in the Global Pediatric Diabetes Management Market in 2024. This dominance is due to their pivotal role in providing comprehensive care and emergency management for pediatric patients with diabetes. Children with type 1 or type 2 diabetes often require specialized medical attention, including accurate diagnosis, insulin therapy initiation, continuous glucose monitoring, and management of acute complications such as diabetic ketoacidosis (DKA). Hospitals are equipped with trained pediatric endocrinologists, multidisciplinary care teams, and advanced medical devices, enabling effective management of complex cases. Hospitals also serve as referral centers for children requiring intensive monitoring or intervention, ensuring access to integrated care solutions that combine insulin delivery systems, continuous glucose monitoring (CGM), and patient education programs. The availability of advanced infrastructure, such as pediatric intensive care units and specialized diabetes clinics, allows for timely treatment and close monitoring, which is critical for maintaining optimal glycemic control and preventing complications.

Download Free Sample Report

Regional Insights

North America emerged as the dominant region in the Global Pediatric Diabetes Management Market in 2024. This is primarily driven by the region’s advanced healthcare infrastructure and high prevalence of pediatric diabetes. The rising incidence of type 1 diabetes among children and adolescents, coupled with an increasing number of type 2 diabetes cases linked to childhood obesity, has created strong demand for effective diabetes management solutions. The presence of well-established healthcare systems, specialized pediatric endocrinology centers, and trained medical professionals ensures timely diagnosis, monitoring, and treatment of pediatric diabetes, making the region a key hub for market growth. The adoption of advanced medical devices, such as continuous glucose monitors (CGM), automated insulin delivery systems, and smart insulin pumps, is particularly high in North America due to favorable reimbursement policies, awareness programs, and government initiatives promoting diabetes care. Hospitals, clinics, and homecare settings are increasingly integrating digital health platforms, telemedicine, and connected monitoring devices, enabling real-time glucose tracking and personalized care.

Recent Developments

• In February 2025, Sanofi-Aventis U.S. LLC received FDA approval for Merilog (insulin-aspart-szjj), a rapid-acting biosimilar to Novolog, for glycemic control in adults and pediatric diabetes patients. Merilog, the first FDA-approved rapid-acting insulin biosimilar, helps reduce mealtime blood sugar spikes and is available as a 3 mL prefilled pen and a 10 mL multiple-dose vial. This marks the third insulin biosimilar cleared by the FDA, enhancing patient access to effective and affordable diabetes treatments.
• In December 2024, Lupin acquired Huminsulin from Eli Lilly in India to strengthen its diabetes portfolio. The acquisition includes Huminsulin R, NPH, 50/50, and 30/70, widely used for managing type 1 and type 2 diabetes in adults and children. Lupin had previously marketed these products through distribution and promotion agreements with Lilly, and the takeover allows full control over the brand, reinforcing its position in the diabetes treatment market.
• In June 2024, Dexcom expanded its Automated Insulin Delivery (AID) system partnerships to the Netherlands, aiming to enhance diabetes management solutions in the region. The expansion allows the company’s continuous glucose monitoring (CGM) technology to integrate seamlessly with multiple insulin pump systems, providing patients with greater flexibility and precision in controlling blood glucose levels. Strategic collaborations with leading industry players, including Omnipod, strengthen Dexcom’s position in the Dutch diabetes care market by offering more comprehensive and connected treatment solutions.
• In June 2023, the U.S. FDA approved Jardiance (empagliflozin) 10 mg and 25 mg tablets for treating type 2 diabetes in children aged 10 years and older, in combination with diet and exercise, according to Boehringer Ingelheim and Eli Lilly. The therapy is not recommended for type 1 diabetes due to increased risk of diabetic ketoacidosis and is unsuitable for patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) as it may be ineffective in this population.

Key Market Players

• Medtronic plc
• DexCom, Inc.
• Abbott Laboratories
• Tandem Diabetes Care, Inc.
• Insulet Corporation
• Novo Nordisk A/S
• Sanofi S.A.
• Eli Lilly and Company
• Roche Diabetes Care, Inc.
• Ascensia Diabetes Care Holdings AG

Report Scope:

In this report, the Global Pediatric Diabetes Management Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Pediatric Diabetes Management Market, By Product:

o   Blood Glucose Monitors (BGM)

o   Continuous Glucose Monitors (CGM)

o   Insulin Pumps

o   Insulin Pens

o   Insulin Syringes

• Pediatric Diabetes Management Market, By Technology:

o   Connected Devices

o   Non-connected Devices

• Pediatric Diabetes Management Market, By End User:

o   Hospitals

o   Homecare

o   Pediatric Clinics

• Pediatric Diabetes Management Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Diabetes Management Market.

Available Customizations:

Global Pediatric Diabetes Management Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Pediatric Diabetes Management Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]